As trust in scientific and regulatory institutions frays and the meaning of “gold standard science” is increasingly contested, cancer research faces a credibility test of its own.
NCI to Implement More Transparent Formula For Calculating Cancer Center Support Grants
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
Earlier this month, NCI released a new Cancer Center Support Grant Notice of Funding Opportunity. Except for the elimination of the Plan to Enhance Diversity component and lengthening of the Shared Resource write-ups from three to six pages, the guidelines are essentially unchanged.
New Year’s Eve approaches, and with it, a chance to turn a new leaf with renewed energy, to reflect on—or perhaps, in the case of 2025, bemoan—the events of the year, and, most importantly, to celebrate.
2025 has, indisputably, been a year of change in oncology as the field grapples with shifting policy directions, RIFs, and uncertainty stemming from the Trump administration’s MAHA mission.
Researchers at MUSC Hollings Cancer Center have identified a promising new weapon in the fight against head and neck cancers. The preclinical drug attacks cancer cells from within by damaging their mitochondria, the cells’ energy factories.
Angelo de Claro was named acting director of the FDA Oncology Center of Excellence, following Richard Pazdur’s departure from that position—and the agency (The Cancer Letter, Dec. 5, 2025).
